"Botulinum Toxin Guidelines Overhauled"
Guidelines for the use of botulinum toxin in various neurological disorders are getting an update, with the best evidence supporting the use of some formulations in spasticity and chronic migraine, researchers reported at the American Academy of Neurology conference. All three botulinum toxin type A formulations are supported by level A evidence for use in upper limb spasticity, and onabotulinumtoxinA (Botox) received a level A recommendation in chronic migraine, although the magnitude of the benefit is small, according to David Simpson, MD, a professor of neurology at the Icahn School of Medicine at Mount Sinai, and colleagues. Learn more.